Background: Data about relapses of onychomycosis after treatment with the new systemic antifungals vary among the different studies, with figures ranging from 3 to 20% for terbinafine and from 21 to 27% for itraconazole, depending on the follow-up duration. Objective: To determine the prevalence of relapses of onychomycosis cured by terbinafine compared with that of onychomycosis cured by itraconazole. Methods: We followed up 47 patients whose toenail onychomycosis had been mycologically cured in an open randomized study comparing intermittent itraconazole treatment with continuous terbinafine treatment and intermittent terbinafine therapy. Patients were examined every 3 months for up to 3 years after the end of therapy. At each visit clinical and mycologic (direct microscopy and cultures) evaluations were performed. Results: Eight of the 36 patients (22.2%) who completed the study had a relapse of onychomycosis during the follow-up period, including 2 patients of the terbinafine 250 mg group, 2 patients of the terbinafine 500 mg group and 4 patients in the itraconazole 400 mg group. As the original infection, the relapse was caused in all cases by Trichophyton rubrum. Conclusions: This study shows that 22.2% of patients with onychomycosis successfully treated with systemic antifungals experienced a relapse. The relapse rate increased from 8.3% at month 12 to 19.4% at month 24 and to 22.2% at month 36. Relapses were more common in patients treated with pulse itraconazole (4/11) than in patients treated with continuous (2/12) or intermittent (2/13) terbinafine. Statistical analysis did not reveal any significant difference between relapse rates in the three groups.

Keywords:
Onchomycosis, Trychophyton rubrum, Trychophyton interdigitale, Dermatophytes, Antifungals, Terbinafine, Itraconazole
1.
De Doncker P, Decroix J, Piérard GE, Roelant D, Woestenborghs R, Jacqmin P, Odds F, Heremans A, Dockx P, Roseeuw D: Antifungal pulse therapy for onychomycosis: A pharmacokinetic and pharmacodynamic investigation of montly cycles of 1-week pulse therapy with itraconazole. Arch Dermatol 1996;132:34–41.
2.
Hofmann H, Bräutigam M, Weidinger G, Zaun H, and the Lagos II Study Group: Treatment of onychomycosis: A randomized, double-blind study with terbinafine and griseofulvin. Arch Dermatol 1995;131:919–922.
3.
Baudraz-Rosselet F, Rakosi T, Wili PB, Kenzelmann R: Treatment of onychomycosis with terbinafine. Br J Dermatol 1992;126(suppl 39): 40–46.
4.
Watson A, Marley J, Ellis D, Williams T: Terbinafine in onychomycosis of the toenail: A novel treatment protocol. J Am Acad Dermatol 1995;33:775–779.
5.
Shear NH, Gupta AK: Terbinafine for the treatment of pedal onychomycosis. Arch Dermatol 1995;131:937–942.
6.
De Cuyper C: Long-term evaluation of terbinafine 250 and 500 mg daily in a 16-week oral treatment for toenail onychomycosis. Br J Dermatol 1996;135:156–157.
7.
Villars VV, Jones TC: Clinical use of oral and topical terbinafine in the treatment of fungal diseases; in Rippon JW, Fromtling RA (eds): Cutaneous Antifungal LAS Agents: Selected Compounds in Clinical Practice and Development. New York, Dekker, 1993, pp 151–168.
8.
Goodfield MJD, Evans EGV: Terbinafine in the treatment of onychomycosis. J Dermatol Treat 1992;3(suppl 1):19–21.
9.
Heikkilä H, Stubb S: Long-term results of patients with onychomycosis treated with itraconazole. Acta Derm Venereol (Stockh) 1997; 7:70–71.
10.
Tosti A, Piraccini BM, Stinchi C, Venturo N, Bardazzi F, Colombo MD: Treatment of dermatophyte nail infections: An open randomized study comparing intermittent terbinafine therapy with continuous terbinafine treatment and intermittent itraconazole therapy. J Am Acad Dermatol 1996;34:595–600.
11.
Marchetti A, Tak Piech C, McGhan WF, Neugut AI, Smith BT: Pharmacoeconomic analysis of oral therapies for onychomycosis: A US model. Clin Ther 1996;18:757–777.
12.
Tosti A, Piraccini BM, Mariani R, Stinchi C, Buttasi C: Are local and systemic conditions important for the development of onychomycosis? Eur J Dermatol, in press.
13.
Buxton PK, Milne LJR, Prescott RJ, Proudfoot MC, Stuart FM: The prevalence of dermatophyte infection in well-controlled diabetics and the response to Trichophyton antigen. Br J Dermatol 1996;134:900–903.
14.
Cribier B, Grosshans E: Efficacité et tolérance de la terbinafine (Lamisil®) dans une série de 50 onychomycoses à dermatophytes. Ann Derm Vénéréol 1994;121:15–20.
15.
Baran R, Badillet G: Un dermatophyte unguéal est-il nécessairement pathogène? Ann Dermatol Vénéréol 1983;110:629–631.
1998
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.